Checkpoint Therapeutics, Inc.

At Checkpoint Therapeutics, our mission is to improve the healthcare system by bringing to market potentially life-saving immunotherapy and targeted cancer treatments with speed, efficacy and at potentially lower prices compared to large pharmaceutical companies. Checkpoint Therapeutics is committed to advancing the development of cancer immunotherapy and targeted oncology treatments by creating accessible, effective and potentially more affordable options for patients everywhere. Along with our leading candidates, cosibelimab and olafertinib, we are dedicated to developing and bringing cancer therapies to market faster and actively pursuing product purchases, in-licensing and co-development opportunities that align with our areas of expertise, offering better patient outcomes and delivering significant value to the future of healthcare. Oliviero is the President and CEO of Checkpoint Therapeutics, a member of Checkpoint’s Board of Directors and has more than twenty years of operational experience in the biotechnology industry. Oliviero was a leading member of the design of several clinical studies and the regulatory oversight of Keryx’s new drug application for Auryxia™, which successfully obtained FDA marketing approval in 2014 and EMA marketing approval in 2015. Oliviero is a CFA charterholder and holds a B.B.A. Oliviero is the President and CEO of Checkpoint Therapeutics, a member of Checkpoint’s Board of Directors and has more than twenty years of operational experience in the biotechnology industry. Oliviero was a leading member of the design of several clinical studies and the regulatory oversight of Keryx’s new drug application for Auryxia™, which successfully obtained FDA marketing approval in 2014 and EMA marketing approval in 2015.